NCT06003231

Who might be able to join this trial:

• You have been diagnosed with one of the following cancers (confirmed by a lab/biopsy): head and neck cancer (from the mouth, salivary glands, voice box, or throat — but NOT the nasopharynx), non-small cell lung cancer, ovarian/fallopian tube/peritoneal cancer, or uterine (endometrial) cancer.
• Your cancer cannot be removed by surgery and has either spread to other parts of the body or come back locally in a way that cannot be operated on.
• Your cancer has gotten worse after receiving platinum-based chemotherapy (the specific requirements vary depending on which cancer type you have — confirm details with trial site).
• For lung cancer: you must also have previously received a specific type of immunotherapy (anti-PD(L)1), unless your doctor determined it was not suitable for you.
• For lung cancer: if you have certain known gene changes (called AGAs), you must have already received a targeted treatment for those changes, if one was available.
• For lung cancer: you must not have had more than 2 previous chemotherapy treatments for advanced disease.
• For ovarian cancer: your cancer must have come back within 6 months or less of finishing platinum-based chemotherapy (known as "platinum-resistant").
• For ovarian cancer: you must not have had more than 4 previous chemotherapy treatments for advanced disease.
• For ovarian cancer: if you have a BRCA gene mutation, you must have already been treated with a type of targeted drug called a PARP inhibitor.
• For endometrial cancer: you must not have had more than 3 previous chemotherapy treatments for advanced disease.
• Your tumor must show a certain level of a protein called HER2 (scored 1+, 2+, or 3+) on a tissue test, OR you have a HER2 gene mutation (confirm with trial site).
• Your cancer must be measurable on a scan using standard criteria (confirm with trial site).
• You must be able to provide a stored or freshly prepared tumor tissue sample.
• You must be generally well enough to carry out light daily activities — scored 0 or 1 on a standard health scale called the ECOG scale (confirm with trial site).

Who may not be able to join:

• You have previously been treated with a drug containing a substance called MMAE (confirm with trial site).
• You have a known allergy or sensitivity to any ingredient in the study drug, disitamab vedotin (confirm with trial site).
• You have been diagnosed with another serious (invasive) cancer within the past 2 years, or still have signs of a previous cancer.
• You have cancer that has spread to the brain or the lining of the brain/spinal cord, and it is currently active and has not been treated.

Important: Always verify eligibility with the trial site directly before applying.